米国企業
BOSTON SCIENTIFIC CORP

BOSTON SCIENTIFIC CORPBSX

時価総額

$1095.2億

PER

68.8倍

	2010年 12月31日	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Net sales	7,806	7,622	7,249	7,143	7,380	8,386	9,048	9,823	10,735	9,913	11,888	12,682	14,240
Cost of products sold	2,599	2,659	2,349	2,174	2,210	2,424	2,593	2,813	3,116	3,465	3,711	3,956	4,345
Gross profit	5,207	4,963	4,900	4,969	5,170	5,962	6,455	7,011	7,620	6,448	8,177	8,727	9,896
Selling, General and Administrative Expense	2,580	2,487	2,535	2,674	2,902	3,099	3,294	3,569	3,941	3,787	4,359	4,520	5,190
Research and development expenses	939	895	886	861	817	920	997	1,113	1,174	1,143	1,204	1,323	1,414
Royalty expense	185	172	153	140	111	79	68	70	65	45	49	47	46
Amortization expense	513	421	395	410	438	545	565	599	699	789	741	803	828
Goodwill, Impairment Loss	1,817	697	4,350	423	-	-	-	-	-	73	-	-	-
Intangible asset impairment charges	65	21	142	53	195	11	4	35	105	460	370	132	58
Intangible asset impairment charges	65	21	142	53	195	11	4	35	105	460	370	132	58
Contingent consideration net expense (benefit)	-	-	-	-	-	29	-80	-21	-35	-100	-136	35	58
Contingent consideration net expense (benefit)	-	-	-	-	-	29	-80	-21	-35	-100	-136	35	58
Restructuring Charges	116	220	355	456	69	28	37	36	38	52	40	24	69
Restructuring Charges	116	220	355	456	69	28	37	36	38	52	40	24	69
Litigation Settlement, Expense	-	-	-	-	1,036	804	285	103	115	278	430	173	-111
Litigation Settlement, Expense	-	-	-	-	1,036	804	285	103	115	278	430	173	-111
Loss (Gain) on Disposal of Businesses and Assets	-	-	-	-	-	-	-	-	-	-	78	-22	-
Loss (Gain) on Disposal of Businesses and Assets	-	-	-	-	-	-	-	-	-	-	78	-22	-
Operating expenses	5,863	4,059	8,768	4,849	5,471	5,515	5,170	5,504	6,102	6,528	6,978	7,078	7,553
Operating expenses	5,863	4,059	8,768	4,849	5,471	5,515	5,170	5,504	6,102	6,528	6,978	7,078	7,553
Operating income (loss)	-656	904	-3,868	120	-301	447	1,285	1,506	1,518	-80	1,199	1,649	2,343
Interest expense	393	281	261	324	216	233	229	241	473	361	341	470	265
Other, net	-14	19	22	-19	8	-37	-124	156	-358	362	218	-38	-93
Income (loss) before income taxes	-	642	-4,107	-223	-509	177	933	1,422	687	-79	1,076	1,141	1,985
Income tax expense (benefit)	2	201	-39	-102	-390	-170	828	-249	-4,013	2	36	443	393
Net income (loss)	-1,065	441	-4,068	-121	-119	347	104	1,671	4,700	-82	1,041	698	1,592
Preferred stock dividends	-	-	-	-	-	-	-	-	-	33	55	55	23
Net income (loss) attributable to Boston Scientific common stockholders	-	-	-	-	-	-	-	-	-	-115	985	642	1,570
Earnings Per Share, Basic	-0.7	0.29	-2.89	-0.09	-0.09	0.26	0.08	1.21	3.38	-0.08	0.69	0.45	1.08
Earnings Per Share, Diluted	-0.7	0.29	-2.89	-0.09	-0.09	0.25	0.08	1.19	3.33	-0.08	0.69	0.45	1.07
Net sales	7,806	7,622	7,249	7,143	7,380	8,386	9,048	9,823	10,735	9,913	11,888	12,682	14,240
Cost of products sold	2,599	2,659	2,349	2,174	2,210	2,424	2,593	2,813	3,116	3,465	3,711	3,956	4,345
Gross profit	5,207	4,963	4,900	4,969	5,170	5,962	6,455	7,011	7,620	6,448	8,177	8,727	9,896
Selling, General and Administrative Expense	2,580	2,487	2,535	2,674	2,902	3,099	3,294	3,569	3,941	3,787	4,359	4,520	5,190
Research and development expenses	939	895	886	861	817	920	997	1,113	1,174	1,143	1,204	1,323	1,414
Royalty expense	185	172	153	140	111	79	68	70	65	45	49	47	46
Amortization expense	513	421	395	410	438	545	565	599	699	789	741	803	828
Goodwill, Impairment Loss	1,817	697	4,350	423	-	-	-	-	-	73	-	-	-
Intangible asset impairment charges	65	21	142	53	195	11	4	35	105	460	370	132	58
Intangible asset impairment charges	65	21	142	53	195	11	4	35	105	460	370	132	58
Contingent consideration net expense (benefit)	-	-	-	-	-	29	-80	-21	-35	-100	-136	35	58
Contingent consideration net expense (benefit)	-	-	-	-	-	29	-80	-21	-35	-100	-136	35	58
Restructuring Charges	116	220	355	456	69	28	37	36	38	52	40	24	69
Restructuring Charges	116	220	355	456	69	28	37	36	38	52	40	24	69
Litigation Settlement, Expense	-	-	-	-	1,036	804	285	103	115	278	430	173	-111
Litigation Settlement, Expense	-	-	-	-	1,036	804	285	103	115	278	430	173	-111
Loss (Gain) on Disposal of Businesses and Assets	-	-	-	-	-	-	-	-	-	-	78	-22	-
Loss (Gain) on Disposal of Businesses and Assets	-	-	-	-	-	-	-	-	-	-	78	-22	-
Operating expenses	5,863	4,059	8,768	4,849	5,471	5,515	5,170	5,504	6,102	6,528	6,978	7,078	7,553
Operating expenses	5,863	4,059	8,768	4,849	5,471	5,515	5,170	5,504	6,102	6,528	6,978	7,078	7,553
Operating income (loss)	-656	904	-3,868	120	-301	447	1,285	1,506	1,518	-80	1,199	1,649	2,343
Interest expense	393	281	261	324	216	233	229	241	473	361	341	470	265
Other, net	-14	19	22	-19	8	-37	-124	156	-358	362	218	-38	-93
Income (loss) before income taxes	-	642	-4,107	-223	-509	177	933	1,422	687	-79	1,076	1,141	1,985
Income tax expense (benefit)	2	201	-39	-102	-390	-170	828	-249	-4,013	2	36	443	393
Net income (loss)	-1,065	441	-4,068	-121	-119	347	104	1,671	4,700	-82	1,041	698	1,592
Preferred stock dividends	-	-	-	-	-	-	-	-	-	33	55	55	23
Net income (loss) attributable to noncontrolling interests	-	-	-	-	-	-	-	-	-	-	-	-	1
Net income (loss) attributable to Boston Scientific common stockholders	-	-	-	-	-	-	-	-	-	-115	985	642	1,570
Earnings Per Share, Basic	-0.7	0.29	-2.89	-0.09	-0.09	0.26	0.08	1.21	3.38	-0.08	0.69	0.45	1.08
Earnings Per Share, Diluted	-0.7	0.29	-2.89	-0.09	-0.09	0.25	0.08	1.19	3.33	-0.08	0.69	0.45	1.07